When should patients with stroke receive thrombolytics?

Journal of Family Practice

Volumn 53, Issue 8, 2004, Pages 656-659

  Adair, Gina ^a   Grant, Joel ^a   Pandhi, Nancy ^a   Saunders, Robert ^a   Sadowsky, Iris ^a   West, Brian ^a   Kerns, J William ^a   Knight, Karen ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; HEPARIN;

BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSENSUS; DRUG DOSE REGIMEN; DRUG UTILIZATION; EVALUATION; FIBRINOLYTIC THERAPY; HUMAN; LOW DRUG DOSE; META ANALYSIS; MORBIDITY; MORTALITY; NEUROIMAGING; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW; STROKE;

ACUTE DISEASE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HUMANS; PLASMINOGEN ACTIVATORS; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 4043082147     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Wardlaw JM, del Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Chichester, UK: John Wiley; 2003.
2. Wardlaw JM, Sandercock PA, Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis. Stroke 2003; 34:1437-1442.
3. Adams HP Jr., Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB et al. Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Heart Association. Stroke 2003; 34:1056-1083.
4. Tissue plasminogen activator for acute ischaemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581-1587.
5. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274:1017-1025.
6. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282:2019-2026.
7. Practice advisory: thrombolytic therapy for acute ischemic stroke-summary statement. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1996; 47:835-839.
8. Hirsh J, Dalen J, Guyatt G; American College of Chest Physicians. The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. Chest 2001; 119(1 Suppl):1S-2S.
9. Bravata DM, Kim N, Concato J, Krumholz HM, Brass LM. Thrombolysis for acute stroke in routine clinical practice. Arch Intern Med 2002; 162:1994-2001.
10. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000; 283:1151-1158.
11. Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzam DM; Cleveland Clinic Health System Stroke Quality Improvement Team. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke 2003; 34:799-800.